Arxiv Universal PublishingsNOVEL TREATMENT APPROACHES IN REACTIVE ARTHRITIS: CLINICAL AND CYTOKINE RESPONSES TO IGURATIMOD 25 MG COMPARED WITH BIOLOGIC AND CONVENTIONAL THERAPIESJavohirMullokulovauthorKhalmuradAkhmedovauthorReactive Arthritis (ReA) is an immune-mediated form of spondyloarthritis, often triggered by genitourinary or gastrointestinal infections. Current therapeutic strategies rely mainly on NSAIDs and cs-DMARDs, with biologics reserved for refractory disease. However, limited progress has been made in exploring novel targeted agents. Iguratimod 25 mg, an oral immunomodulatory drug approved for rheumatoid arthritis in Asia, has demonstrated anti-inflammatory and cytokine-suppressive properties, but evidence in ReA is scarce2025-12-08"Research Science and Innovation house" LLCMaqola

For work being deposited by its own author: In self-archiving this collection of files and associated bibliographic metadata, I grant Arxiv Universal Publishings the right to store them and to make them permanently available publicly for free on-line. I declare that this material is my own intellectual property and I understand that Arxiv Universal Publishings does not assume any responsibility if there is any breach of copyright in distributing these files or metadata. (All authors are urged to prominently assert their copyright on the title page of their work.)

For work being deposited by someone other than its author: I hereby declare that the collection of files and associated bibliographic metadata that I am archiving at Arxiv Universal Publishings is in the public domain. If this is not the case, I accept full responsibility for any breach of copyright that distributing these files or metadata may entail.

Clicking on the Deposit Item Now button indicates your agreement to these terms.